Background. Copy number variants (CNVs) have been shown to increase risk for physical anomalies, developmental, psychiatric and medical disorders. Some of them have been associated with changes in weight, height, and other physical traits. As most studies have been performed on children and young people, these effects of CNVs in adulthood are not well established.
INTRODUCTION
Human height, weight and other anthropometric traits are highly heritable. Genetic factors contribute up to 80% of height (1, 2) , and genome-wide association studies (GWAS) suggest that the total additive effect of single nucleotide variants (SNVs) explain 56% of variance in height and 27% of body mass index (BMI) variability (3) . Hand grip strength's heritability has been estimated at 56% (4) . Resting heart rate, systolic and diastolic blood pressure are also highly heritable, with estimates of 61%, 54% and 49% respectively (5) .
While SNVs tend to have small effect sizes, large copy number variants (CNVs) have been shown to have profound effects on weight and height, with 16p11.2 deletions and duplications providing a striking example (6) . Other recognised CNVs with large effect sizes on physical traits are deletions at distal 16p11.2, associated with obesity (7) and at 1q21.1, associated with microcephaly and short stature (8) . Failure to thrive has been described in some carriers of 3q29 duplications (9) while short stature has been associated with the classical and distal 22q11.2 deletions (10) . Individuals with severe early-onset obesity have an increased rate of large and rare deletions (11) . Obesity can be a feature in rare syndromic monogenic disorders (12) , which include several of the CNVs analysed in the current study: 1q21.1 deletion, 15q11-q13 duplication, 16p11.2 classic and distal deletions and 22q11.2 duplication.
Most of the published research has been based on children or young people referred for genetic testing for developmental delay, congenital malformations and autism spectrum disorders, i.e. some of the most affected individuals. Such individuals may not be typical of carriers of CNVs, and importantly for long term health outcomes, the impact of these CNVs in adults, especially in those who have not been diagnosed as CNV carriers in early life, is not well described. In addition, most reports focus on a single, or at most a limited number of CNVs, making it difficult to perform comparative studies of the impact of individual CNVs on physical measures. Another potential problem is that small sample sizes will miss more subtle changes in physical traits.
The largest study on CNVs and anthropometric measures was performed on 191,161 unrelated European adults (13) Here we report an analysis of the full UK Biobank cohort. We tested 54 CNVs that have been proposed to be pathogenic and were carried by at least five participants. We analysed these CNVs for association with an extended set of 16 physical traits (Methods), that include anthropometric traits (weight, height, BMI, waist, hip, waist/hip ratio), and other physical traits relevant to human health: pulse rate, blood pressure, arm strength, peak expiratory volume, heel bone mineral density, and the fat percentage of legs, arms and trunk. These traits have been associated with adverse health outcomes and increased mortality (14) (15) (16) (17) (18) (19) .
RESULTS:
The 54 CNVs and 16 traits produce 864 phenotype/CNV associations ( Supplementary Table   1 ). Of those, 272 were nominally significant (at p < 0.05), a much higher number than the 43 expected by chance. Using Benjamini-Hochberg's false discovery rate (FDR), 214 of those were significant at 0.1 (marked in bold in Supplementary Table 1 ). Images of the changes in the physical traits associated with each CNV, and their 95% confidence intervals (95%CI), are shown in Supplementary Figure 1 and on our institutional website (http://kirov.psycm.cf.ac.uk/Physical measurements: search by CNV). Table 1 summarises the significant findings. It is restricted to CNVs that have at least one significant association at FDR = 0.1, with the direction of the effect indicated with + or -. To simplify the presentation, we grouped together the three fat % measures to indicate any change on arm, leg or trunk fat % measures and we don't show waist and hip circumferences, as the waist/hip ratio contains this information. Figure 1 shows the distribution of changes for the three CNVs with the largest number of significant associations (13 each). The significance also depends also on sample size, so these are not necessarily the most pathogenic CNVs. Figure 1 and Table 1 
about here
Mirror phenotypes A number of reciprocal deletions/duplications at the same locus show significant differences in opposite directions (as explained in the Discussion, no CNV is associated with increased physical strength or peak expiratory flow). We decided to use a simple definition for a CNV that produces a mirror phenotype: at least one measure should be changed in opposite directions, both significantly different from controls at FDR = 0.1. Using this definition, we find seven mirror image CNVs: 1q21.1, 2q13, 16p11. phenotype, but didn't reach our criteria for inclusion, most likely due to the small number of observations. We note these two studies are not fully independent, as a third of the present sample was used in the earlier paper. CNVs. Some of these associations are already known from previous large case series (e.g. 16p11.2 deletion/duplication, 16p11.2 distal deletion), or from studies on individuals with syndromic short stature or obesity (Introduction), supporting the validity of this dataset and our methods. Many significant associations have not been reported before in systematically assessed cohorts, and certainly not as part of the same analysis, i.e. using identical methods to allow comparisons between CNVs. We show that the majority of these CNVs (41 of the 54) impact on at least one physical trait. For example, we find that deletions in NRXN1, a CNV so far known to increase risk for schizophrenia and autism spectrum disorders (20) (21) (22) , are associated with a plethora of adverse changes, producing 11 significant results, such as increased weight, BMI, waist/hip ratio, fat percentage in arms, legs and trunk, and a faster pulse rate. NRXN1 carriers also have reductions in muscular strength, peak expiratory flow and heel bone mineral density. Carrier status of 15q11.2 deletions and duplications have not been consistently associated with medical or anthropometric changes, although deletions increase risk for neurodevelopmental disorders (21, 23) . We now show that deletion carriers have significant changes in over half of the measures, most notably reductions in height and birth weight, and increases in bone mineral density and waist/hip ratio. 15q11.2 duplication carriers have increased BMI, fat percentage and waist circumference and reduced muscular strength ( Supplementary Table 1 and Figure 1 ). The magnitudes of the changes associated with 15q11.2 are small (e.g. deletion carriers are only 1.5cm shorter in height on average), but the very large sample size of the UK Biobank (~1600 deletion and ~1900 duplication carriers) allows small changes to be detected with high statistical confidence. Another notable finding is the association of 22q11.2 duplications with 10 measures. Although high rates of psychiatric disorders have been recorded for this CNV (24) , increased weight has been reported only in single duplication carriers until now, and due to the extreme phenotypic variability of this condition, its true pathogenicity has been regarded as unclear (25) . We report on a much larger sample (>260 carriers) and observe that central obesity (increased BMI and waist-to-hip ratio) is the leading feature in duplication carriers, making this CNV potentially highly pathogenic in relation to health-related outcomes (18, 26) .
CNVs cause adverse effects of likely medical relevance. We note that most (although not all) of the observed effects are likely to be adverse for health. Thus, all 35 significant associations with physical strength and peak expiratory flow are in the direction of reduced performance. Both measures are associated with increased mortality (14, 16) . Most associations with pulse rate and blood pressure are in the direction of higher values, indicating a worse cardiovascular performance. Many CNVs cause increased weight/ fat percentage/ central obesity (increased waist/hip ratio), well-known factors increasing morbidity and mortality (15, 18, 26) . Despite these substantial changes, both types of carriers have average BMI. A widely accepted measure of obesity, that has adverse effect on health outcomes, is the waist/hip ratio, which has been shown to better predict the risk for myocardial infarction (26) . We find this significantly increased in 13 CNVs, including the 1q21.1 duplication, while no CNV caused a significantly reduced ratio, i.e. we do not see any protective effects for medical outcomes, even for CNVs that lead to reduced weight. Our findings that duplications at 15q11.2, 15q13.3, 16p13.3, 22q11.2 and deletions at NRXN1 are among the CNVs with the highest rates of adverse changes on physical measurements, were unexpected and raise important issues regarding the management of such carriers.
Are the effects primary or secondary? Some of the changes in physical traits could be due
to life-style differences among CNV carriers, or to concomitant medication given for diseases caused by the CNVs, rather than to a direct biological effect from gene dosage changes.
Current knowledge of CNV effects are largely restricted to childhood, while the UK Biobank population is composed of older adults, a difference that may result in lifestyle-related effects in this cohort. Reduced muscular strength, lower peak expiratory flow, faster pulse rate, increased weight and fat percentage can all be consequences of reduced exercise and lifestyle changes. Having a pathogenic CNV might make the person less likely to exercise, due to medical, cognitive or social problems. However, it appears that lifestyle is unlikely to account for all the changes we report. Thus, it cannot explain why at least seven CNV loci have opposite (mirror) phenotypes in deletion and duplication carriers ( Figure 2 ) and why four CNVs lead to reduced weight (1q21.1 deletion, 2q13 duplication, 13q12.12 duplication and 16p11.2 distal duplication). The 1q21.1 duplication carriers present with increased height and weight, which together with the macrocephaly reported in children with this duplication (8) suggests that this is an overgrowth syndrome (27) , although with a variable expressivity (8) . Such observations indicate that many of the changes are a direct consequence of gene dosage changes, rather than secondary to life-style or social factors. In fact, each CNV has its own unique signature of physical traits, which become apparent on a heatmap image ( Figure   3 ). Our work provides an unbiased comparison between these patterns among adults, as all Biobank participants were assessed with the same methods and blindly to their CNV status. Carriers of these CNVs could therefore benefit from general monitoring for cardiovascular risk factors and weight gain. It is tempting to envisage the targeting of genes or biochemical pathways in order to improve weight or fat distribution in humans. From this perspective, the CNVs with the most pronounced "mirror" phenotypes ( Figure 2 ) are likely to contain the most promising candidate genes, as gene dosage changes lead to reciprocal changes in the measurements.
MATERIALS AND METHODS
Approval for the study was obtained from the UK Biobank under project 14421: "Identifying the spectrum of biomedical traits in adults with pathogenic copy number variants (CNVs)". CNV calling. We downloaded from the UK Biobank the raw intensity (CEL) files from Affymetrix BiLEVE (N~50,000) and Axiom (N~450,000) arrays and processed them with Affymetrix Power Tools (www.affymetrix.com/estore/partners_programs/programs/developer/tools/powertools.affx) and PennCNV (28) . We followed the same CNV calling pipeline that we described previously (29) . We then called a list of 92 CNVs proposed to be pathogenic, including their reciprocal deletions/duplications (23, 30) . After excluding CNVs with fewer than five observations, and three small CNV loci that produced false-positive calls (two of them telomeric), we took forward 54 CNVs for analysis of associations. Supplementary Table 2 lists the CNVs and the reasons for exclusion or retention in analysis.
Physical measurements. We obtained data from the UK Biobank on tests, which were performed at the assessment centres and described as "physical measurements" (biobank.ctsu.ox.ac.uk/crystal/docs/Bodycomposition.pdf). These include anthropometric measures (height, weight, BMI, hip and waist circumference), body fat content, hand grip strength, spirometry, ultrasound heel bone densitometry and self-reported birthweight. Body fat content is estimated from the bioimpedance measures performed with a Tanita BC418MA body composition analyser. We also included pulse rate and blood pressure, as recorded at the assessment centres. In order to maximise statistical power and simplify the presentation of the results, we only used tests collected on >50% of individuals and excluded variables correlated at >0.9, such as measures collected on left and right arm or leg. We therefore only analysed measures performed on the right arm or right leg and averaged the two pulse rate measures that were performed at the same initial visit. Following research that highlights the importance of the waist to hip ratio (26), we added this measure too, resulting in a set of 16 variables ( Table 2) . Table 2 about here Statistical analysis. We filtered out poorly performing arrays using the following cut-off criteria: genotyping call rate < 0.96, > 30 CNVs per person, a waviness factor of < -0.03 & > 0.03 & LRR standard deviation of > 0.35. We excluded people who self-report to be other than white British or Irish and first-degree relatives (using the kinship coefficients data). This left 396,725 people for analysis. The tested variables followed normal distributions, therefore we did not further transform the data prior to analysis, other than to normalise all measures into z-scores, for a uniform presentation. We used linear regression analysis (glm) in R (version 3.3.2) to test the effect of the CNV carrier status on each measure (in z-score differences). For co-variates we used sex, age, array type (Axiom/BiLEVE), Townsend deprivation index (as a measure of the socioeconomic status) and the first 15 principal components from the genetic analysis, as provided by the UK Biobank. We also provide the changes in non-normalised (original) units, to give more real-world view of the effect of CNV carrier status (e.g. kg, beats per minute, mmHg). We did not control for education or occupation, as we have shown that these can be consequences of CNV carrier status (29) . A Bonferroni correction for 864 test gives a level of significance of p < 5.8×10 -5 , which is conservative, given many of the measures are correlated (e.g. BMI and waist/hip ratio). We used instead the Benjamini-Hochberg FDR = 0.1 as our significance threshold (31) , which corresponded to a nominal p-value of < 0.025 for the current study (Supplementary Table 1 ). 
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